A breakthrough to reduce risk of HIV in adolescents and adults weighing at least 35 kg. WHO releases the new guidelines ...

The US Food and Drug Administration (FDA) has accepted MSD’s doravirine/islatravir (DOR/ISL) new drug application (NDA) for ...

The Food and Drug Administration (FDA) has accepted the New Drug Application for doravirine/islatravir (DOR/ISL) for adults with virologically-suppressed HIV-1 infection.

According to a phase 1 trial, the experimental HIVconsvX vaccine is safe and immunogenic among sub-Saharan African participants who bear the highest burden of HIV-1.

The success and pathogenicity of HIV-1 largely resides in the function of the viral protein Nef. Here, the authors propose that Nef modulates a T cell's ability to form an immunological synapse ...

COVID paused prevention efforts, which helped fuel the rise in new infections. Now federal funding cuts threaten to disrupt ...

GENEVA, (CMC)-The World Health Organization (WHO) on Monday advised countries, including those in the Caribbean to ensure ...

A breakthrough HIV drug that only needs to be injected twice a year to offer near-total protection from the virus and ...

The World Health Organization (WHO) has recommended the global use of injectable lenacapavir (LEN) twice a year to provide near-total ...

SA has accepted an offer of just over R520-million from the Global Fund to Fight Aids, TB and Malaria to buy the twice-a-year ...

This isn’t about managing the AIDS pandemic. It’s about ending it — and letting a new generation grow and thrive free of its ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...